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S _qary Loss ofheterozygosity (LOH) on chromosome 13 occurs on 25-30% of breast tumours. This may
reflect the inactivation of the retinobLastoma susceptibility gene RBI. However, recently another candidate
tumour-suppressor gene has been identified on chromosome 13 by lnkage analysis, the breast cancer
susceptibility gene BRCA2. To mvestigate the mvolvement of BRCA2 in sporadic breast cancer 200 breast
tumours were tested for LOH on chromosome band 13ql2-ql4, ing 11 highly polymorphic microsatellite
markers. LOH was found m 65 tumours, which all showed simultaneously loss of BRCA2 and RBI. Of 12
breast tumour cell lines tested with polymorphic microsatel}ite markers, seven showed a contiguous region of
homozygosity on 13ql2-ql4, g LOH in the tumour from which the cell line had been derived. One
cell line showed homozygosity in the BRCA2 region and heterozygosity at RBI. This is the only indication
that BRCA2 is a distint target for LOH on chromosome 13 in addition to RB).
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Loss of heterozygosity (LOH) on chromosome 13 occurs in
approximately 25% of primary breast tumours (Devilee and
Cornelisse, 1994). As LOH is thought to reflect the inactiva-
tion of one allele of a tumour-suppressor gene, the retino-
blastoma susceptibility gene (RB)), present on chromosomal
band 13q14 could be the target for these LOH events. Struc-
tural abnormalities in RB) have been reported in primary
breast cancs and in breast cancer cell lines (Lee et al., 1988;
rAng et al., 1988; Varley et al., 1989). However, allele loss
at the RB) locus in breast and also in ovarian carcinomas is
not correlated with loss of RBl protein expression (Borg et
al., 1992; Dodson et al., 1994; Kim et al., 1994). This sug-
gests the presence of another tumour-suppressor gene adja-
cent to RB).
The breast cancer susceptibility gene, BRCA2, has recently
been localised to 13ql2-ql3 by genetic lnkage analysis
(Wooster et al., 1994a). In common with the BRCAJ gene on
chromosome 17q21 (Miki et al., 1994), mutations in BRCA2
confer susceptibility to early-onset breast cancer in women
and to ovarian cancer, but the latter risk is probably lower
than for BRCA). In contrast to BRCAJ, BRCA2 is
associated with a substantially increased risk ofbreast cawer
in men.
To investigate further the roles of BRCA2 and RBI in
breast cancer development we have determined LOH in the
13ql2-ql4 chromosomal region in 200 sporadic breast car-
cinomas using 11 polymorphic microsatellite markers.
Materials an m
The 13ql2-ql4 polymorphic microsatellite markers used
were D13S289, D13S290, AFM238zd9, AFM109xhl,
D13S260, D13S171, D13S267, D13S219, D13S218, D13S155
and D13S153 (within RB)). (Gyapay et al., 1994; J Weissen-
bach, personal communication). Polymerase chain reaction
(PCR) was performed as described previously (Abeln et al,
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1994; Wooster et al., 1994b). The PCR products were elect-
rophoresed on denaturing polyacrylanide gels and visualised
by autoradiography. Signal intensites were measured on a
Molcular Dynamics Phosphorlmager 445 SI. Molecular
Dynamics Im uaNT Software was used for quantification
of PCR products. The allelic imblanc (Al) factor is the
quotient of the peak ratio from tumour and constitutional
DNA. An AI factor of 1.5 or lower is interpreted as reten-
tion of heterozygosity, whereas an Al of 2.0 or higher
signifies LOH (Devilee et al., 1994).
DNA was isolated from 200 freshly frozen breast tumours
and 12 breast tumour cell lines. The corresponding constitu-
tional DNA was obtained from peripheral blood samples or
from sikin samples. The breast tumour cell lnes used in this
study are lsted in Table I. The tumour cell lines had no
corresponding normal DNA with which to compare the
results. Therefore the publshed allele frequencies of each
alele at all markers were used to calculate the probability of
the wild-type DNA being homozygous at each locus. It was
then possible to calculate the probability of the DNA being
homozygous throughout the BRCA2 and RBI regions in the
germine DNA (Table I), e.g. the probability that cell line
MDA157 has a contiguous zone of homozygosity for the
markers D13S260, S171, S267, S219 and S218 is
1:895 656
Rests and
Table I represents the results obtaied from the LOH
analysis of200 sporadic breast carcinomas using 11 polymor-
phic microsatellte markers in the 13q12-q14 chromosomal
region. In total 65 tumours (32.5%) show LOH for at least
one informative marker on chromosome 13q. The results
confirm cumulative results of LOH on 13q from several
literature reports, i.e. 25% LOH in 450 informative breast
tumours (Devilee and Cornelisse, 1994).
Evaluation of the role of somatic mutations of BRCA2 in
sporadic cancers is complicated by the presence of the RBI
gene in the vicinity. Since RBI shows structural abnor-
malities in 15% of the primary breast tumours tested (T'Ang
et al., 1988; Varley et al., 1989), much of the LOH on 13q
could be directed at RBI. However, expression of the RBI
gene on chromosomal band 13q14 in tumours of the breast
or the ovary does not correlate with LOH on chromosomeLoss dh_okdbity a BA2
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13q (Borg et al., 1992; Dodson et al., 1994; Kim et al., 1994).
Absence of RBJ staining is found in 15% of the breast
tumours tested, and detected predominantly in tumours with-
out LOH on 13q (Kim et al., 1994). The incongruity between
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may reflect the involvement of BRCA2 as a target for
LOH.
The results shown in Table II indicate that all tumours
which showed LOH at RBI also showed LOH within the



















































Fugwe 1 LOH results for the three tumours with a breakpoint in the BRCA2 region. Phospholmager traces are shown for those
markers that determine the breakpoints and for several adjacent markers. The upper graph represents the signal intensities for the
two alleles in constitutional DNA, the lower graph is tumour DNA. The peaks representing the two alleles are indicated '1' and '2'.
L, loss of heterozygosity; R, retention ofheterozygosity; N, not informative; NA, no available data. Numbers in the graphs signify
the allelic imbalance factors, e.g. marker D13S267 in tumour BTl9 has lost allele '1' and the allele imbalance factor is 4.6.
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Tae I Results of 12 breast tumour ceIl fines tested with microsatellite markers in the 13q12-q14 rgon: allele
frequencies are shown between brackets for cel lines with a contiguous stretch of homozygous markers
AFM
Cell line 238zd9 D13S260 D13S171 D13S267 D13S219 D13S218 D13S155 D13SJ53
MDA-MB-157 * (0-24) M (0.11) * (0.01) * (0.29) * (0.01) * (0.35) U -
MDA-MB-231 * (NA) * (0.01) * (0.01) * (0.44) * (0.36) * (0.42) * U
MDA-MB-361 * (0.02) * (0.09) * (0.32) * (0.29) * (0.36) U (0.42) * O
MDA-MB468 * (0.16) U (0.04) U (0.32) * (0.29) U (0.36) * (0.14) U U
T47D * (0.28) * (0.13) NA * (0.44) * (0.36) * (0.14) * U
BT2O * (0.28) M (0.41) * (0.32) * (0.17) U (0.36) * (0.14) * U
BT474 * (0.17) * (0.11) * (0.32) M (0.17) * (0.36) * (0.14) * U
MDA-MB-415 0 U 0 * * * 0 U
SKBR3 * D D O 0 O 0 0
DU44-77 * * * * 0 U 0 D
MCF7 NA D 0 * * D NA NA
ZR-75-1 U (0.16) * (0.41) * (0.32) * (0.17) * (0.36) NA 0 D
0, Heterozygous; *, homozygous; NA, no available data.
Table U LOH results in the 13q12-q14 region obtained with 11
microsatellite markers in 200 breast tumours
Category No. of twnouwrs Perceage
Retention of all 13q markers 135 67.5
LOH of all informative markers 62 31
LOH only in the BRCA2 region 0 0
LOH only in the RBI region 0 0
Brkpoint within the BRCA2region 3 1.5
BRCA2 showed LOH at RBI. Analyses using markers
between the two loci (D13S218 and D13S219) indicate that
the allele losses involve a contiguous region of the
chromosome including both BRCA2 and RBI. Since LOH
usually involves larg chromosomal regions and because
BRCA2 and RB) are only 20cM apart, the loss of both loci
has most probably occurred through a single genetic event. It
is, however, possible that a growth advantage is conferred
upon neoplastic cells by simultaneous inactivation of both
genes. Either way, our results do not clarify whether BRCA2
or RBI is the predominant target of the LOH on
chromosome 13q.
Three tumours were identfied which showed a transition
from retention of heterozygosity to LOH at an adjacent
marker, defined as a 'breakpoint', within the BRCA2 region
as defined by linkage analysis (Wooster et al., 1994a). BTl9
had a breakpoint between D13S260 and D13S171. BT42 and
BT589 were not informative for D13S171. They showed a
brekpoint between D13S260 and D13S267. Figure 1 shows
the allelic imbalance factors and the Phosphorimager traces
of the PCR products obtaied from these tumours using the
markers that border the breakpoints. On the assumption that
BRCA2 is the target for LOH in these tumours the results
suggest that the candidate region for this gene is now
decreased to 3 cM and defined by D13S260 (proximal) and
D13S267 (distal). However, since all three breakpoint
tumours also show LOH ofRB), and hence RB) may be the
tret of LOH, this mapping information may be
misleading.
In addition to the 200 primary breast tumours, 12 breast
cancer cell lines were examined. Although corresponding
DNA from non-neoplastic issue was not available, each
polymorphic marker used is beterozygous in a minimum of
64% ofthe cases (and usually more). It is therefore extrmly
unlikely that an individual will be constitutionally
homozygous for all polymorphisms in the chromosome
13q12-ql4 region. Since 7 of the 12 cell lines were
homozygous at all markers examined it is likely that allele
loss has occurred during development of the tumour or
subsequently during culture in vitro. Table I shows the cell
lnes and the aliele frequencies for cases with a contiguous
region of homozygosity. The high frequency of plausible
allele loss in the RBI region in cell lines (7 out of 12, 58%)
compared with that in primary tumours (32.5%) corresponds
well with the observation of rAng et al. (1988) that rear-
rangements in RB) occur more frequently in breast cancer
cell lines than in primary breast tumours, suggesting an
enhancement of cell line establishment as a result of RBI
inactivation.
Of particular interest is ZR-75-1. This cell line is
homozygous at all markers within or adjacent to the BRCA2
region but is heterozygous at both polymorphisms close to
RBI, D13S155 and D13S153. The probability of such a
contiguous zone ofhomozygosity in the BRCA2 region is less
than 1:4000. This number is the multiplication sum of the
allele frequencies for all markers in the BRCA2 region (Table
I) and additionally from marker D13S220 (located between
D13S267 and D13S219), ofwhich the frequency for the allele
in ZR-75-1 is 0.18. The results therefore suggest that this
individual was constitutionally heterozygous at at least one
marker but that LOH has occurred in the BRCA2 region and
not at RBI. Consequently ZR-75-1 is the only breast cancer
in this series indicating that BRCA2 is a distinct target for
LOH on chromosome 13q in addition to RBI. However, we
cannot exclude that LOH in the BRCA2 region occurred
during cell lne establishment and was not present in the
primary tumour. The results from ZR-75-1 do not decrease
the idate region for BRCA2.
We have recently analysed allele loss on chromosome 13q
in breast cancers from a family showing strong evidence of
linkag to BRCA2. Seven out of eight informative tumours
showed LOH and in all cases it was the wild-type allele that
was lost (Collins et al., 1995). This observation in familial
breast cancer and the presence of LOH on 13q above back-
ground rates in sporadic breast cancer support the hypothesis
that BRCA2 is inactivated during oncogenesis. However, the
role of mutations of BRCA2 in sporadic breast cancer re-
mains unclear. The results presented here do not support or
exclude the possibility that BRCA2 is the target of LOH on
chromosome 13q in sporadic breast cancer.
Tlhis work was supported by Cancr Research Campaign, South
Thames Regional Authority Breakthrough Breast Cancer Charity
and the Dutch Cancer Society ([KW 91-04).
1dmso es
ABELN ECA, CORVER WE, KUIPERS-DUKSHOORN NJ, FLEUREN
G-J AND CORNELISSE CJ. (1994). Mokcular genetic analysis of
flow-sorted ovarian tumour cells: improved detection of oss of
heterozygosity. Br. J. Cacer, 7S, 255-262.
BORG A, zHANG Q-X ALM P, OLSSON H AND SELLBERG G. (1992).
The retinolastoma gene in breast cancer: allele os is not cor-
related with loss of Wm proten expresson Cancer Res., 52,
2991-2994.Los d 1ozyity a 2
e A-M Cleton-Jansen etal
192AA
COLLINS N. MCMANUS R. WOOSTER R, MANGION J, SEAL S, LAK-
HANI S. ORMISTON W. DALY P. FORD D, EASTON D AND
STRATTON M. (1995). Loss of the wild-type chromosome in
breast cancers from BRCA2 gene carriers. Oncogene, 10,
1673-1675.
DEVILEE P AND CORNELISSE CJ. (1994). Recent developments in
the molecular genetics of breast cancer. Crit. Rev. Oncogenesis, 5,
247-270.
DEVILEE P. SCHOTHORST EM. BARDOEL AFJ, BONSING BA.
KUIPERS-DUKSHOORN N. JAMES MR, FLEUREN G-J, VAN DER
MEY AGL AND CORNELISSE CJ. (1994). Allelotype of head and
neck paragangliomas: allelic imbalance is confined to the long
arm of chromosome 11, the site of the predisposing locus PGL.
Genes Chrom. Cancer. 11, 71-78.
DODSON MK. CLIBY WA. XU H-J. DELACEY KA. HU S-X. KEENEY
GL. LI J. PODRATZ KC. JENKINS RB AND BENEDICT WF.
(1994). Evidence of functional RB protein in epithehal ovarian
carcinomas despite loss of heterozygosity at the RB locus. Cancer
Res.. 54, 610-613.
GYAPAY G. MORISSETTE J. VIGNAL A. DIB C. FIZAMES C,
MILASSEAU P. MARC S. LATHROP M AND WEISSENBACH J.
(1994). The 1993-4 Genethon human genetic linkage map.
Nature Genet., 7, 246-339.
KIM TM. BENEDICT WF. XU H-J. HU S-X. GOSEWEHR J,
VELICESCU M. YIN E. ZHENG J, D'ABLAING G AND DUBEAU L.
(1994). Loss of heterozygosity on chromosome 13 is common
only in the biologically more aggressive subtypes of ovarian
epithelial tumors and is associated with normal retinoblastoma
gene expression. Cancer Res., 54, 605-609.
LEE EY-HP, TO H. SHEW J-Y. BOOKSTEIN R, SCULLY P AND LEE
W-H. (1988). Inactivation of the retinoblastoma susceptibility
gene in human breast cancers. Science, 241, 218-221.
MIKI Y. SWENSEN J. SHATTUCK-EIDENS D. FUTREAL PA. HAR-
SHMAN K, TAVTIGIAN S, LIU Q, COCHRAN C. BENNETT LM,
DING W. BELL R. ROSENTHAL J. HUSSEY C. TRAN T. MCCLURE
M. FRYE C. HATTIER T. PHELPS R, HAUGEN-STRANO A. KAT-
CHER H. YAKUMO K. GHOLAMI Z. SHAFFER D AND STONE S.
(1994). A strong candidate for the breast and ovarian cancer
susceptibility gene BRCAI. Science, 266, 66-71.
TANG A. VARLEY JM. CHAKRABORTY S, MURPHREE AL AND
FUNG Y-KT. (1988). Structural rearrangement of the retinoblas-
toma gene in human breast carcinoma. Science, 242, 263-266.
VARLEY MJ. ARMOUR J. SWALLOW JE, JEFFREYS AJ. PONDER
BAJ. TANG A, FUNG Y-KT. BRAMMAR WJ AND WALKER RA.
(1989). The retinoblastoma gene is frequently altered leading to
loss of expression in primary breast tumours. Oncogene, 4,
725-729.
WOOSTER R. NEUHAUSEN SL. MANGION J. QUIRK Y. FORD D.
COLLINS N. NGUYEN K. SEAL S. TRAN T. AVERILL D. FIELDS
P. MARSHALL G. NAROD S. LENOIR GM, LYNCH H.
FEUNTEUN J. DEVILEE P. CORNELISSE CJ, MENKO FH, DALY
PA. ORMISTON W. MCMANUS R. PYE C, LEWIS CM. CANNON-
ALBRIGHT LA. PETO J. PONDER BAJ. SKOLNICK MH. EASTON
DF. GOLDGAR DE AND STRATTON MR. (1994a). Localization of
a breast cancer susceptibility gene, BRCA2. to chromosome
13ql2-13. Science, 265, 2088-2090.
WOOSTER R. CLETON-JANSEN AM, COLLINS N. MANGION J. COR-
NELIS RS. COOPER CS. GUSTERSON BA. PONDER BAJ. VON
DEIMLING A. WIESTLER 0. CORNELISSE CJ, DEVILEE P AND
STRATTON MR. (1994b). Instability of short tandem repeats
(microsatellites) in human cancers. Nature Genet., 6, 152-156.